UNSPSC 51451902: Flurantel

This classification denotes an antihelminthic agent with the molecular formula C19H12F6N2O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3Q14SL1C0O, chemically known as 2,6-dihydroxy-3-nitro-3,5-bis(trifluoromethyl)benzanilide diacetate (ester). but generally known as flurantel, which bears US NIH Compound Identifier 219070. European Medicines Agency schedules Flurantel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07743MIG.

UNSPSC 51451902 Flurantel, a Commodity code, does not align with the recent state and local procurement activity tagged to it. The four most recent opportunities—solicitations for naloxone and drug deactivation systems, a therapeutic pharmacy initiative RFI, first-aid supplies for fire rescue, and generic multi-source pharmaceuticals through a cooperative purchasing vehicle—cover naloxone, opioid-reversal kits, emergency medical consumables, and generic pharmaceuticals, but none reference flurantel or antiparasitic agents. The code appears to be either misapplied to these opportunities or unused in current state and local procurement under its correct scope.

Recent activity shows issuing bodies across multiple jurisdictions and agency types: Seminole County, Florida (county health procurement); the Texas Health and Human Services Commission (state agency); the City of Tampa (municipal fire department); and the Minnesota Multistate Cooperative Purchasing Alliance serving state and local government members including Oregon. Geographic spread spans Florida, Texas, Minnesota, and Oregon, with activity concentrated in health and emergency services procurement. The Seminole County IFB (IFB60459723LAS, due Jul 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually; the City of Tampa IFB (26P00145, due Mar 13, 2026) solicited 169 line items of medical and first-aid supplies for fire rescue, estimated at $700,000.00 and sheltered to certified Small Local Business Enterprises; the Texas HHS RFI (HHS0017013, due Apr 3, 2026) explored direct-to-manufacturer prescription programs; and the MMCAP RFP (S1070000015802, due Mar 26, 2026) sought generic and OTC pharmaceutical products through authorized wholesalers. No recent opportunities explicitly reference flurantel or antiparasitic pharmaceuticals.